Iwan de Esch

Iwan de Esch


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2005 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
RLRob Leurs
Rob Leurs
RBRemko A. Bakker
Remko A. Bakker
HTHenk Timmerman
Henk Timmerman
IEIwan de Esch
Iwan de Esch

20 September 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
OLOscar P. J. van Linden
Oscar P. J. van Linden
AKAlbert Kooistra
Albert Kooistra
RLRob Leurs
Rob Leurs
IEIwan de Esch
Iwan de Esch
CGChris De Graaf
Chris De Graaf

18 October 2011 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CGChris De Graaf
Chris De Graaf
AKAlbert Kooistra
Albert Kooistra
HVHenry F. Vischer
Henry F. Vischer
Vsevolod KatritchVsevolod Katritch
Vsevolod Katritch
MKMartien Kuijer
Martien Kuijer
RLRob Leurs
Rob Leurs

22 October 2015 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
AKAlbert Kooistra
Albert Kooistra
GKGeorgi K. Kanev
Georgi K. Kanev
OLOscar P.J. van Linden
Oscar P.J. van Linden
RLRob Leurs
Rob Leurs
IEIwan de Esch
Iwan de Esch
CGChris De Graaf
Chris De Graaf
Protein kinases play a crucial role in cell signaling and are important drug targets in several therapeutic areas. The KLIFS database contains detailed structural kinase-ligand interaction information derived from all (>2900) structures of catalytic domains of human and mouse protein kinases deposited in the Protein Data Bank in order to provide insights into the structural determinants of kinase-ligand binding and selectivity. The kinase structures have been processed in a consistent manner by systematically analyzing the structural features and molecular interaction fingerprints (IFPs) of a predefined set of 85 binding site residues with bound ligands. KLIFS has been completely rebuilt and extended (>65% more structures) since its first release as a data set, including: novel automated annotation methods for (i) the assessment of ligand-targeted subpockets and the analysis of (ii) DFG and (iii) αC-helix conformations; improved and automated protocols for (iv) the generation of sequence/structure alignments, (v) the curation of ligand atom and bond typing for accurate IFP analysis and (vi) weekly database updates. KLIFS is now accessible via a website (http://klifs.vu-compmedchem.nl) that provides a comprehensive visual presentation of different types of chemical, biological and structural chemogenomics data, and allows the user to easily access, compare, search and download the data.

1 December 2005 in Drug Discovery Today
Verified
Journal Article
Closed access
SCSylvain Celanire
Sylvain Celanire
MWMaikel Wijtmans
Maikel Wijtmans
PTPatrice Talaga
Patrice Talaga
RLRob Leurs
Rob Leurs
IEIwan de Esch
Iwan de Esch

21 October 2020 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
GKGeorgi K Kanev
Georgi K Kanev
CGChris De Graaf
Chris De Graaf
BWBart A. Westerman
Bart A. Westerman
IEIwan de Esch
Iwan de Esch
AKAlbert Kooistra
Albert Kooistra
Kinases are a prime target of drug development efforts with >60 drug approvals in the past two decades. Due to the research into this protein family, a wealth of data has been accumulated that keeps on growing. KLIFS—Kinase–Ligand Interaction Fingerprints and Structures—is a structural database focusing on how kinase inhibitors interact with their targets. The aim of KLIFS is to support (structure-based) kinase research through the systematic collection, annotation, and processing of kinase structures. Now, 5 years after releasing the initial KLIFS website, the database has undergone a complete overhaul with a new website, new logo, and new functionalities. In this article, we start by looking back at how KLIFS has been used by the research community, followed by a description of the renewed KLIFS, and conclude with showcasing the functionalities of KLIFS. Major changes include the integration of approved drugs and inhibitors in clinical trials, extension of the coverage to atypical kinases, and a RESTful API for programmatic access. KLIFS is available at the new domain https://klifs.net.